In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on OraSure Technologies OSUR with a Buy rating, but lowered the price target from $12.00 to $8.00.
In the report, Jefferies noted, “Concerns around weaker demand trends in OSUR's legacy product franchises have contributed to precipitous multiple compression, which we view as overdone. Following a better 1Q13 experience, evidence of incremental base business stability should work to rekindle investor enthusiasm for its intermediate-term growth opportunities. With OSUR's new OTC HIV & rapid HCV tests still in their infancy, we assume coverage at Buy / $8 target.”
OraSure Technologies closed on Thursday at $4.47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
